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EDITORIAL REVIEW
Glomerular actions of nitric oxide
The discovery of the L-arginine-nitric oxide (NO) pathway has
been one of the major scientific accomplishments of the last 10
years [1—71. NO, a simple molecule, has been identified as having
roles in cell communication as well as cell defense and injury. This
has changed our understanding of important aspects of the
physiology and pathophysiology of the cardiovascular, nervous
and immune systems [5, 8—14].
A family of enzymes named NO synthases (NOS) are capable of
generating NO from the terminal guanidino nitrogen of L-
arginine. NOS require reduced nicotinamide adenine dinucle-
otide, flavine dinucleotide, flavine mononucleotide and tetrahy-
drobiopterine as co-factors in the oxidative process which results
in production of citrulline and NO from L-arginine [2, 4, 5,
13—17]. Four isoforms of NOS have so far been identified: in the
brain, vascular endothelial cells, macrophages and in hepatocytes.
The brain NOS, which is also present in peripheral neural tissue,
and the endothelial NOS are constitutive (c) enzymes which are
calcium and calmodulin dependent [13, 14, 17]. The macrophage
NOS is calcium and calmodulin independent and is not constitu-
tive but can be induced (iNOS) by certain cytokines and bacterial
products, such as endotoxin [15, 18—21]. Most recently a structur-
ally distinct iNOS has been induced in hepatocytes (with endo-
toxin), which is calcium independent but requires calmodulin [22,
23]. iNOS have also been identified in other cells, including
glomerular mesangial cells [24—26], vascular endothelial cells [5]
and vascular smooth muscle cells [27]. Thus far transcription
factors NF-KB and IRF-1 have been shown to particpate in the
induction of iNOS [7].
The endothelial cNOS, which is predominantly membrane
bound, is activated by mechanisms that result in calcium mobili-
zation, including activation of receptors by various agonists such
as acetylcholine (ACh), bradykinin (BK) and ADP as well as by
physical forces, specifically shear stress [5, 14, 28, 29]. The amount
of NO generated by cNOS is small, in nmol quantities, and its
effects are transient since NO is rapidly inactivated by superoxide
anions and binding to hemoglobin [5]. However, since endothelial
cNOS is tonically active in vivo, there is a continual basal
production of NO by vascular endothelium [5, 11, 12]. On the
other hand, iNOS synthesize NO in large (mmol) quantities. Since
iNOS are regulated at the transcriptional level the initiation of
NO synthesis/release is delayed after the stimulus (by several
hours) but once initiated the synthesis of NO is long lasting
(hours) [5, 15, 19, 24].
In early studies differentiation between cNOS and iNOS was
based upon its dependence or independence, respectively, of
calcium for activation. However, recent studies have shown that
certain calcium dependent NOS are inducible [30, 31]. L-arginine
analogs compete with L-arginine for binding sides in the NOS and
can inhibit NO synthesis by both cNOS and iNOS [5, 32, 33].
Several L-arginine analogs have been synthesized and some of
these analogs may have more affinity for either the constitutive or
inducible enzymes [5, 32, 33]. Actinomycin D and cycloheximide,
inhibitors of DNA transcription and of protein synthesis, respec-
tively, prevent the induction of NOS. Glucocorticoids and certain
cytokines such as TGF/3, IL-4 and IL-b have also been found to
inhibit iNOS without affecting cNOS [7, 34—37]. In human
monocytes cross linking of the surface receptor CD69 which is
constitutively expressed leads to production of NO in large
quantities by these cells [38].
NO acting as a messenger molecule mediates vascular relax-
ation, inhibits platelet aggregation and adhesion to the endothe-
hum and modulates leukocyte chemotaxis and adhesion [5, 39,
40]. All these effects of NO are mediated by activation of soluble
guanylate cyclase after NO binding to its heme iron, resulting in
increased levels of cyclic guanosine, 3', 5', monophosphate
(cGMP) [5, 32]. NO also mediates relaxation of vascular smooth
muscle by directly activating calcium-dependent potassium chan-
nels [391. In peripheral blood mononuclear cells NO may act as a
signaling molecule by activating G proteins through a cGMP-
independent pathway [40—42]. NO, when released in large quan-
tities by the iNOS, can inhibit enzymes such as aconitase and
ribonucleotide reductase by nitrosylation of Fe-S centers [43—45].
It needs to be stressed that a differentiation has to be made
between NO action and the activity of NO synthases. The actions
of NO are dependent upon: (1) the amount of NO produced,
which is conditioned by the availability of its substrate L-arginine
as well as the activity of the NOS; (2) the rate of NO inactivation
by either superoxide anions or NO sequestration due to binding to
reactive groups such as heme groups; and (3) the availability of
substrates such as guanylate cyclase which participate in mediat-
ing NO actions. Increments in NOS are often accompanied by
increased NO action; however, increased NO production and
activity may under certain circumstances be due to changes in
NOS activity without changes in NOS mass [46, 47].
In the kidney cNOS, identified by immunohistochemical stain-
ing or by reverse transcription and polymerase chain reactions,
has been found in glomeruli and vasculature as well as the macula
densa, the collecting duct and the inner medullary thin limb [47,
48]. In addition, iNOS occurs in vascular smooth muscle and
granular cells at the juxtaglomerular apparatus (JGA) [48], and
cytokine induced iNOS have been reported in cultured proximal
and collecting duct cells [48—51].
Glomerular hemodynamic actions of NO
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The pressures and flows at the glomerulus that determine single
nephron GFR (SNGFR) are controlled by the tone of preglo-
merular (afferent) and postglomerular (efferent) arteriolar resis-
tance vessels (RA and RE). The ratio of the tone of these
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resistances determines the glomerular blood pressure, gC and the
overall level of tone in the renal resistance vessels controls
glomerular plasma flow [52—54]. The glomerular capillary ultra-
filtration coefficient, K1, is another variable that can directly
influence SNGFR and dynamic control may occur via alterations
in tone of glomerular mesangial cells which cause alterations in
filtration surface [52, 531.
The glomerular mesangium is located centrally in the glomer-
ulus and plays an important role in regulation of the glomerular
microcirculation [55—571. The fenestrated glomerular endothe-
hum lies in direct contact with the mesangium, hence, substances
released by the endothelium or circulating in the plasma have easy
access to the mesangial cells. In addition, substances released by
either endothelial or mesangial cells can act in a paracrine fashion
[56—61]. Mesangial cells have actin and myosin, and similarly to
vascular smooth muscle cells, can contract and relax. Vasoactive
agents such as angiotensin II, vasopressin, endothelin and throm-
boxane A2, induce mesangial contraction subsequent to binding
to specific receptors and activation of phospholipase C, ultimately
leading to calcium mobilization [59].
Effects of acute blockade of NO
In several species, systemic administration of L-arginine ana-
logs produces dose dependent and prolonged increases in arterial
blood pressure (BP) and renal vasoconstriction with falls in renal
plasma flow (RPF) and smaller declines in GFR [5, 12, 62—67].
These effects can be reversed by excess L-arginine, which suggests
that the L-arginine analogs are functioning as specific NO synthe-
sis inhibitors [5, 62, 63, 66, 68]. Direct infusion of NO synthesis
inhibitors into the renal artery of the isolated perfused rat kidney
and L-arginine depletion in the perfusion medium produces renal
vasoconstriction and falls in GFR [65, 69—72]. There are regional
differences in the extent to which NO controls the circulation and
the renal vasculature seems to be particularly sensitive to regula-
tion by NO. Systemic infusion of low doses of NO inhibitors,
which have no effect on BP, produce increased renal vascular
resistance (RVR) and reductions in renal blood flow (RBF) and
cortical blood flow [64, 73, 74].
In vivo micropuncture experiments have shown that systemic
administration of pressor doses of NO synthesis inhibitors pro-
duce complex effects on the glomerular microcirculation. Both RA
and RE increase and as a result glomerular plasma flow falls;
however, SNGFR is relatively protected due to a large rise in gC
[75, 76]. In addition, the glomerular capillary ultrafiltration coef-
ficient (I(f) is reduced to —50% of control with NO blockade [75,
76]. In vitro studies utilizing co-incubation of either glomerular or
aortic endothelial and mesangial cells have shown that agonist-
induced release of NO from endothelial cells is accompanied by
increases in mesangial cell CGMP [60, 61]. Increases in cGMP
induced by NO are sufficient for antagonizing angiotensin II (Ang
II) evoked mesangial cell contraction [60]. Atrial natriuretic
peptide which increases mesangial cell cGMP via activation of the
particulate guanylate cyclase, also antagonizes the effects of Ang
II [77]. Thus, independent of the triggering stimulus, increases
in cGMP antagonize mesangial cell contraction (or induce its
relaxation) probably due to inhibition of cellular calcium mobili-
zation.
Systemic administration of NO blockers produce widespread
inhibition of NO synthesis and increases in BP, which will have
indirect effects on the kidney. Local intrarenal inhibition of NO
generation leads to much smaller increases in RVR than are seen
during systemic NO blockade; thus, a substantial part of the renal
vasoconstriction seen with systemic NO inhibition is due to
secondary phenomena perhaps mediated via the renal nerves.
Micropuncture studies in the rat [76] have shown that whereas
both RA and RE increase with systemic NO blockade, a smaller
increase in RA is seen during intrarenal blockade (Fig. 1). The
smaller increase in RA with intrarenal versus systemic NO block-
ade probably reflects an autoregulatory component of the in-
crease in RA when BP rises [78]. Although RE increases with
systemic NO blockade, there is no effect on R when NO synthesis
is blocked locally within the kidney (Fig. 1). These observations
suggest that in the euvolemic rat the cortical afferent arteriole is
tonically under the control of locally produced NO whereas RE is
not [76]. In vitro studies on isolated microperfused cortical rabbit
arterioles have supported these findings [79—81], although in
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Fig. 1. Comparison of the effects of systemicJ___ versus intrarenal NO blockade on afferent and
efferent arteriolar resistances in the euvolemic
Munich Wistar rat. *Significant change versus
control by paired t-test. These studies are
reported in [76].
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contrast to cortical vessels, NO synthesis inhibition produced
constriction of both afferent and efferent arterioles of juxtamed-
ullaiy nephrons [821. Thus, in vivo and in vitro studies suggest that
tonic release of NO and control of basal tone by NO is confined
to the afferent arteriole and mesangial cell in the cortex, but in the
juxtamedullary nephron preparation, efferent arterioles are also
under tonic NO control.
In some situations the efferent arteriole from the cortex can
make and respond to NO. In the isolated perfused rat kidney, the
extremely high perfusion rate causes a high shear stress effect
throughout the renal microcirculation and shear is a potent
stimulus to release of endothelial NO [5, 29]. In this setting both
RA and RE increase with NO blockade [831. There is also evidence
that agonists stimulate NO release from efferent arterioles (see
below).
NOS is abundant in the juxtaglomerular apparatus [48, 51, 84,
85] and NO generated within the macula densa may control
glomerular hemodynamics. The macula densa provides the sensor
for the tubuloglomerular feedback system (TGF), and when NO
synthesis in the macula densa is locally inhibited, gcdecreases
due to constriction of the afferent arteriole [86]. In vitro studies
have shown that inhibition of macula densa NO synthesis during
delivery of high NaCI produced afferent arteriolar constriction
but had no vasoconstrictor effect during delivery of low sodium
chloride [871 (Fig. 2). These studies suggest that TGF-induced
afferent arteriolar vasoconstriction produced by increased NaCI
reabsorption at the macula densa is blunted or modified by NO,
which is also stimulated by high NaCI [86, 87]. Conflicting
preliminary observations suggest that decreased macula densa
NaCI reabsorption stimulates NO synthesis [88, 89]. Resolution of
these differences, as well as defining the role and regulation of an
iNOS in the afferent arteriole [48] remains to be determined. The
relationship between NO and renin release is discussed below.
Effects of chronic blockade of NO
Chronic blockade of NO produces a dose dependent, chronic
hypertension [901. Partial NO blockade over a two month period
produced a moderate, stable systemic hypertension with renal
vasoconstriction, proteinuria and mild glomerular sclerotic injury
[90]. Micropuncture revealed that was high, Kf was low and
both RA and RE were elevated [91], which is a similar pattern of
change to that seen after acute systemic NO blockade [75, 76].
More complete NO blockade for four to six weeks produced
severe hypertension with renal vasoconstriction and substantial
microvascular and glomerular damage, characteristic of hyperten-
sive microangiopathy [92]. After only two weeks of severe NO
blockade, BP and were higher than after two months of the
more moderate dose of NO blocker [90, 93]. With severe chronic
NO blockade there is a progressive increase in BP and RVR,
declines in GFR and development of proteinuria, within three
weeks [94]. With even shorter periods of chronic NO inhibition (3
to 7 days), sustained renal vasoconstriction has been reported [95,
961, although in the Brattleboro rat, the increase in RVR is not
maintained over a three day period [97].
Overall, the studies with acute and chronic NO blockade
suggest that NO plays important short- and long-term roles in
control of glomerular hemodynamics by controlling RA and the
tone of glomerular mesangial cells and in some circumstances,
RE. Thus all contractile cells which control glomerular filtration
are potential targets for endogenous NO.
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Fig. 2. Changes in the internal diameter of the isolated rabbit afferent
arteriole during local NO synthesis inhibition at the macala densa using
L-NAME. L-NAME was added to the macula densa perfusate which
contained either a high NaCI (•) or a low NaCI (0) solution. tP < 0.001
versus control (that is, intact NO system), < 0.003 for low versus high
NaCI. This Figure is reproduced from the Journal of Clinical Investigation
92:1093—1098, 1993 by copyright permission of the American Society for
Clinical Investigation and permission from the authors [87].
NO and renal autoregulation
A combination of myogenic and TGF mechanisms increase RA
during increases in systemic BP, which leads to autoregulation of
RBF, GFR and gc [78]. In addition to controlling TGF (see
above) it is possible that NO also influences the myogenic
component of autoregulation. The isolated rabbit ear is a weakly
autoregulating vascular bed under normal conditions, but block-
ade of local NO production leads to improved pressure-depen-
dent autoregulation [98]. In the kidney, NO synthesis inhibition
leads to increases in RVR but autoregulation of RBF and
appropriate changes in tone in afferent arterioles of the rat
juxtamedullary nephrons persist over a wide range of arterial BP
[82, 99—102]. There is a suggestion that in dogs and rats, NO
might contribute to the vasodilation which occurs at low pressure
[101, 103, 82]; however, renal autoregulatory ability is relatively
unaffected by the activity of the NO system.
Effects of vasodilators that stimulate NO
The vasodilatory action of ACh and BK is mediated in part by
NO [1, 5, 12]. Both ACh and BK are potent renal vasodilators and
glomerular micropuncture studies indicate that both RA and RE
respond to ACh and BK with a vasodilation [104]. In vitro studies
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have also indicated that RA vasodilates to ACh, [82, 105, 106] and
RE relaxes in response to ACh and BK [106]. In contrast to these
observations, studies by Kon, Harris and Ichikawa suggested that
the main renal artery was the primary site of NO release in
response to ACh, since endothelial denudation of the renal artery
impaired the vasodilatory response to ACh by RA and RE [107].
However, the in vitro evidence indicates that NO can be generated
in the renal arterioles, thus, a vasoconstrictor may have been
released by endothelial rubbing of the renal artery [107].
Despite renal vasodilation and increased plasma flow with both
ACh and BK, SNGFR did not rise due to an offsetting decline in
Kf [1041. The reduction in K with BK (and possibly ACh)
probably resulted from a direct action on the mesangium to
increase intracellular free calcium and inositol trisphosphate [108,
109], which overwhelmed the endothelial NO-stimulated effect to
relax the mesangial cell [60].
The increase in urinary cGMP and the renal vasodilatory action
of ACh and BK can be attenuated or abolished by simultaneous
NO synthesis inhibition [12, 110]. ACh induced increases in
cortical and papillary blood flow and falls in RA in juxtamedullary
nephrons are also inhibited by simultaneous NO inhibition [73,
82]. However, NO is not the only mediator of ACh and BK
induced renal vasodilation, since a significant arachidonic acid
component has been identified in rat and dog kidney [72, 111—
113].
ACh and BK produce widespread vasodilation but amino acid
infusion and high protein feeding produce a selective renal
vasodilation which is linked to increases in urinary cyclic GMP
excretion [114]. In the anesthetized rat, the renal vasodilatory
response to an infusion of amino acids is inhibited by NO
blockade [115, 116], although mechanisms in addition to NO may
contribute to the renal vasodilation in response to amino acid
infusion [117]. Why NO release in response to amino acid infusion
should be confined to the kidney, has yet to be described.
Interactions between NO and other vasoactive systems
The greater the level of vascular tone, the greater the amount
of endothelial NO produced [118]. How much the vasoconstrictor
response to NO blockade results from withdrawal of an "active"
NO vasodilatory stimulus and how much is secondary to amplifi-
cation of underlying vasoconstrictor systems, is not clear. Below
interactions between NO and other vasoactive control systems will
be considered.
Angiotensin II
In the anesthetized rat and in vitro juxtamedullary nephrons,
part of the renal vasoconstriction in response to NO synthesis
inhibition is due to the unopposed vasoconstrictor effect of
endogenous Ang II [82, 115, 119]. In contrast, Ang 11 blockade has
no effect on the renal vasoconstrictor response to acute NO
inhibition in the conscious, unstressed rat [120] and similar
findings have been reported in the anesthetized rat [121]. Sigmon
and Beierwaltes have indicated that the Ang II dependence of the
renal vasoconstriction seen with NO blockade varies according to
the preparation, being much less pronounced in the awake animal
[122]. Inhibition of Ang II has no attenuating effect on the
vasoconstriction due to NO blockade in isolated rat afferent
arterioles [123] and in glomerular micropuncture studies, Ang II
inhibition had no effect on the increase in RA although blunting of
the increase in R was seen [124]. Thus, the renal vasoconstriction
produced by acute NO blockade does not require the participa-
tion of the Ang II system; however, when Ang II levels are
sufficiently high to control renal vascular tone, NO is important in
maintaining renal perfusion. In the conscious rat and dog, infu-
sions of Ang II that have little effect on RVR when given alone,
cause massive renal vasoconstriction when the NO system is also
acutely inhibited [125, 126]. In rabbit isolated afferent arterioles,
locally produced NO blunts the response to administered Ang II
but RE, which is also responsive to Ang II, is unaffected by NO
blockade [79, 80]. When endogenous Ang II levels are elevated in
two kidney, one-clip Goldblatt hypertension, tonically produced
NO helps maintain perfusion to the contralateral kidney but does
not apparently have an impact on resistance in the clipped kidney
which is mainly controlled by Ang II [127]. In fact, NO may not
have a long- term protective vasodilatoiy effect on the renal vas-
culature when intrarenal Ang II levels are chronically high [128].
In chronic NO blockade, Ang II plays an important role in the
maintenance of the hypertension since chronic Ang II inhibition
prevents the hypertension and the kidney damage during NO
blockade [91, 123, 129]. When the Ang II system is acutely
inhibited in chronic NO blockade induced hypertension, there is
no beneficial effect on BP or RVR [151] but when both Ang II and
the sympathetic nervous system (al-adrenergic receptors) are
inhibited simultaneously, normalization of BP occurs although the
renal vasoconstriction is largely maintained [130].
In addition to influencing the renal vascular effect of Ang II,
NO may also influence the levels of Ang II via control of renin
release. This is a controversial area and some observers have
suggested that NO stimulates renin release [13 1—133] whereas
others suggest that NO is inhibitory on renin release, thus acute
NO blockade increases renin production [134—136]. Although the
reasons for these discrepancies regarding the directional effect of
NO on renin release remain unclear, there is recent evidence to
suggest that NO may have a dual effect on renin production.
When applied directly to the granular cells NO inhibits renin
secretion, however, stimulation of macula densa NO production,
leads to a stimulation of renin secretion [85]. In models of chronic
NO blockade, renin levels are variable and have been reported as
low, unchanged or elevated, which probably reflects the severity
and extent of the hypertension and underlying renal pathology as
well as any direct actions of NO deficiency on renin release [89,
91, 129].
Sympathetic nervous system (SNS)/catecholamines
Although NO will blunt any vasoconstrictor tone present,
several groups have shown that the acute increase in BP with NO
blockade is not dependent on the sympathetic nervous system.
Ganglion blockade, pithing or adrenergic receptor blockade had
little effect on the increases in BP or RVR [121, 137], although
this contrasts with one report which suggests that the hypertension
and renal vasoconstriction can be abolished by ganglion blockade
[138]. There is some evidence to suggest that efferent renal
sympathetic nerve activity plays an important role in mediating
the renal vasoconstriction during acute systemic NO blockade,
and the hypertension during chronic NO blockade [65, 139]. The
combination of acute Ang II and SNS blockade also normalize BP
in chronic NO blockade-induced hypertension [130] Thus, as with
Ang II, the SNS in some circumstances plays an important role in
NO dependent peripheral and renal vasoconstriction.
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Endothelin (ET)
There are both ETA and ETB receptors in the kidney and is
some evidence suggests that ET-induced renal vasoconstriction is
via ETB stimulation [140, 1411. ET1 administration produces renal
vasoconstriction in the rabbit, dog and rat, and in all cases
inhibition of either NO synthesis or cGMP potentiates the renal
vasoconstrictor effects of ET1 [142—1451 However, the inter-
relationship between the vasodilation mediated by NO and vaso-
constriction elicited by several vasoconstrictor substances is fur-
ther complicated by the fact that vasoconstrictors such as ET1 and
platelet activating factor (PAF), trigger endothelium dependent
relaxations mediated by NO. In the isolated rabbit afferent
arteriole, ET1 causes a dose dependent vasoconstriction which is
amplified by NO synthesis inhibition and attenuated by the NO
stimulator ACh [146]. PAF vasodilates preconstricted isolated
rabbit afferent arterioles via increased local NO production [147],
and lowers RE via NO produced in the glomerulus [148]. Of
interest, ET and PAF, as well as substances released by platelets
during aggregation, that is, serotonin and ADP, and by-products
of blood coagulation such as thrombin, stimulate NO synthesis!
release in the presence of an intact endothelium but trigger
vascular smooth muscle and mesangial cell contraction when
acting directly on these cells [28]. Therefore, the ultimate action
of these substances depends upon whether or not a functionally
intact endothelium is interposed between the agonist and the
mesangial or vascular smooth muscle cell. Obviously, this has
important pathophysiologic implications. It is known that in
coronary vessels serotonin, for instance, is a mild vasodilator in
the presence of an intact endothelium and a vasoconstrictor when
the endothelium is dysfunctional [149]. If the same situation
occurs within the glomerulus, a given substance may induce
opposite changes in the glomerular microcirculation depending
upon whether the glomerular endothelium is functionally intact.
Pro staglandins
There are a number of agents with receptors on the vascular
endothelial cell which release both NO and vasodilatory prostan-
oids, such as ACh, BK [51. There is also evidence to suggest that
the endothelial prostaglandins may control the synthesis of NO.
Prostacyclin (PGI2) inhibits NO release from cultured bovine
aortic endothelial cells and modulates LPS stimulated iNOS in
mouse macrophages [150, 151]. It has been suggested that agents
which increase cAMP, such as P012, decrease NO production
[152]. There is also in vivo data to suggest that in the dog kidney
the full renal vasodilatory potential of NO is expressed only in the
presence of PG blockade [112, 113]. In contrast to these findings,
however, an in vitro study suggests that POE2 actually mediates
cytokine stimulated activation of iNOS in rat liver macrophages
[153], and it has also been shown that NO stimulates the inducible
cyclooxygenase enzyme (COX2) in vitro [154]. Functional studies
in the normal and chronically NO blocked conscious rat have
shown that indomethacin has little potentiating effect on either
the pressor or the renal vasoconstrictor response to either acute,
low dose or systemic chronic NO blockade [74, 155]. Thus,
according to the circumstance, inhibition or stimulation have been
observed between NO and cyclooxygenase products.
In control of vascular tone and renal hemodynamics NO has a
complex relationship with other vasoactive systems, which vary
according to experimental preparation, volume status, anesthesia,
etc. Tonically produced NO both attenuates the renal vasocon-
strictor effects of any activated pressor systems and provides an
active renal vasodilatory stimulus.
Role of NO in some disease states where glomerular
hemodynamics are deranged
Since chronic pharmacologic NO inhibition causes hyperten-
sion, renal vasoconstriction and kidney damage, NO deficiency
might also be causal in other forms of hypertension. There is
evidence to suggest that the normal, "normotensive" response to
high dietary salt intake includes stimulation of NO production
[156]. Studies in the Dahl salt sensitive (SS) hypertensive rat
suggest that malignant hypertension with renal function impair-
ment and damage develops due to a deficient NO response to
dietary salt [157]. Low dose NOS inhibition, which has no effect
on BP in dogs on normal salt intake, leads to hypertension during
high salt intake [158, 159]. Also, salt loading greatly potentiates
the hypertension and glomerular injury in rats receiving high dose
NO blockade [159], although sodium restriction does not amelio-
rate the hypertension [160]. Despite the findings described above,
it is unlikely that alterations in NO synthesis or release can fully
explain salt dependent hypertension. Moreover, in hypertensive
Afro-Americans without renal failure, salt loading suppressed
serum levels of N02/NO3 [161].
The role of NO is less well defined in other types of hyperten-
sion. The vasodilatory response to ACh in the afferent arteriole is
attenuated in both the spontaneously hypertensive rat (SHR) and
in Goldblatt hypertension [105, 162], although at least with SHR
this does not appear to be due to NO deficiency [1051. In renal
ablation-induced hypertension, increased intrarenal NO may
cause the preglomerular vasodilation [163]; however, it has also
recently been reported that L-arginine supplementation is protec-
tive [164]. Thus the role of NO in ablation induced injury remains
unclear. Direct measurements of NO released by kidneys from
hypertensive rats revealed that compared with kidneys from
normal rats, renal NO synthesis/release was normal in kidneys
from hypertensive SHR rats but it was markedly decreased in
kidneys from Dahl-S rats and DOCA-salt rats [165]. This suggests
that in the setting of hypertension, high dietary salt may have an
independent negative effect upon NO synthesis/release or action,
a phenomenon previously observed in studies of vascular re-
sponses in rats given high dietary salt [166].
Acute renal failure induced by renal ischemia is associated with
a loss of responsiveness to the endothelium dependent vasodila-
tors ACh and BK [167]. However, NOS activity is paradoxically
increased in this model [168], a response that has also been
reported in gentamicin-induced acute renal failure [169]. Defi-
cient NO production has been implicated in glycerol-, uranyl
nitrate- and cyclosporine-induced nephrotoxicity since L-arginine
is protective in these models [170—172], although the mechanism
of the protective effect of L-arginine remains to be determined.
Excess NO production may be pathogenic in some situations.
For example, recent experimental studies have suggested that
excess NO synthesis early in diabetes may be responsible, at least
in part, for the glomerular hyperfiltration which characterizes this
disease. Glomerular damage develops in diabetes and is preceded
and possibly caused by falls in RA and high P5 [173] and an
increase in NO has been implicated [174—176]. The rise in P5 and
consequent glomerular damage would be further aggravated in
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the presence of a concomitant increase in systemic blood pressure.
Poorly controlled diabetes results in increased glycosylation of
proteins and formation of advanced glycosylation end-products
(AGEs). AGEs have been shown to biologically inactivate NO,
impairing NO stimulation of guanylate cyclase [177]. AGEs have
also been suggested to participate in the genesis of the vascular
disease which accompanies diabetes [177]. Therefore it is possible
that the L-arginine/NO pathway is involved in diabetes in a
bimodal fashion characterized by an early NO excess and followed
by a functional deficiency when the disease advances [175—178].
Whether manipulation of the L-arginine/NO pathway can modify
the natural history of diabetic nephropathy is at present unclear.
The role of NO in endotoxic shock is discussed below.
NO and the sepsis syndrome
Nitric oxide inhibits platelet aggregation and adhesion to
collagen [5, 41, 178]. PG12 synergizes with NO in inhibiting
platelet aggregation but has no effect on platelet adhesion [41].
However, platelets can generate their own NO when stimulated to
aggregate with collagen, ADP or arachidonic acid [5]. In vitro,
L-arginine inhibits platelet aggregation induced by these agents,
and these effects of L-arginine can be inhibited by a substituted
L-arginine analog such as L-NMMA which inhibits NO synthesis
[5]. The platelet NOS, similar to that present in the endothelium,
is calcium dependent and may play an important autocrine role
synthesizing NO and increasing platelet cGMP in response to
many stimuli which foster platelet aggregation. However, strong
platelet aggregating substances such as thrombin cannot be
inhibited by L-arginine supplementation during the aggregating
process, but can be inhibited in vitro by addition of PGI2. In vivo
inhibition of NO synthesis with L-arginine analogs does not result
in platelet aggregation and thrombosis in the absence of other
stimuli [179].
Fibrin deposition is a variable component of most forms of
glomerular injury [180, 181]. Platelet adhesion and fibrin deposi-
tion has been observed in most forms of immune- as well as in
hemodynamically-mediated glomerular injury. Moreover, in dis-
eases in which intravascular coagulation is a predominant feature,
such as uremic hemolytic syndrome, post-partum renal failure,
and in certain cases of gram negative sepsis, diffuse glomerular
thrombosis is common [180—182]. Given the particular anatomy
of the glomerulus, the anti-thrombogenic action of NO may be
important, particularly its synergistic effect with PGI2 which is also
synthesized by both endothelial cells and mesangial cells.
Induction of NOS in rat mesangial cells has been shown
recently by several laboratories [24—26]. Incubation of mesangial
cells with lipopolysacchride (LPS) of gram negative bacteria
and/or several cytokines, such as tumor necrosis factor (TNF), y
interferon and IL-i results in increased mRNA for iNOS and in
synthesis of NO, detectable by the cumulative increase in N02/N0,
(oxidation products of NO), in the culture media [24]. In addition,
synthesis of NO by mesangial iNOS is accompanied by increases
in mesangial cGMP, therefore suggesting that within the glomer-
ulus NO of mesangial origin may have autocrine as well as
paracrine effects [24—26]. Rats given LPS in vivo have an increase
in serum and urinary excretion of N02/N0I [179]. Glomeruli
isolated from these rats continue to produce N02/N0, cx vivo in
tissue culture. The in vivo and cx vivo synthesis of NO in response
to LPS can be inhibited by L-NAME [179].
During gram negative sepsis, multiple biological systems are
activated [182]. Endotoxin, the LPS component of the wall of
gram negative bacteria is the triggering agent. Some of the
biological responses observed during sepsis are mediated directly
by LPS while others are mediated by the secondary synthesis and
release of other mediators such as TNF, various interleukins,
platelet activating factor (PAF), and components of the comple-
ment and the coagulation cascade [182]. Recent studies have
suggested that the decrease in inotropic property of cardiac
muscle, as well as the profound vasodilation (often resistant to
vasopressors) observed during septic shock may be mediated by
NO [5, 183—186]. Several studies in vivo and in vitro have found
evidence of high levels of synthesis of NO by iNOS in vascular
smooth muscle and mesangial cells [24, 27, 186]. In vivo the
hypoterision induced by either LPS or TNF can be reversed with
L-NMMA, a NOS inhibitor [183, 184]. Although the demonstra-
tion of iNOS in humans has been more elusive, two lines of
evidence suggest that NOS can be induced. (a) The vasopressor
resistant hypotension of septic shock in humans can be improved
with an intravenous administration of L-NMMA [185] and (b)
recently two studies have shown increased NO synthesis in
humans. One of the studies provided direct evidence of NO
synthesis from L-arginine [187]. In this study patients were given
N'5 L-arginine and increased serum N'5 N02/N02/NOW, was
measured during IL-2 administration [187]. Similar increases in
NO synthesis have been reported by Ochoa et al in septic patients
[188].
Glomerular thrombosis occasionally severe enough to result in
cortical necrosis has been observed in humans with sepsis. Studies
by Shultz and Raij have shown, in rats, that LPS induces increased
NO synthesis in vivo [179]. Inhibition of NO synthesis with
L-NAME resulted in diffuse glomerular thrombosis after LPS
administration, but inhibition of NO synthesis without LPS ad-
ministration did not result in glomerular thrombosis [179]. In
glomerular thrombosis induced by LPS, plus L-NAME can be
prevented by concomitant administration of NO donnors such as
GTN but not by other vasodilators [184].
These findings suggest that endogenous synthesis of NO in
sepsis and sepsis related syndromes may have, in fact, a renopro-
tective role by maintaining renal vasodilation and by inhibiting
platelet adhesion and aggregation [5, 179].
Within the glomerulus TNF, IL-i and PAF can be released
locally by either activated mesangial cells and/or blood borne
macrophages [51, 1891. These same mediators induce endothelial
synthesis of tissue factor and plasminogen inactivator, two sub-
stances which foster platelet adhesion and blood coagulation,
respectively [57, 190]. Under these circumstances the local release
of PG!2 and NO would be important in preventing glomerular
thrombosis. Moreover, plasminogen activator has been shown to
potentiate NO synthesis by IL-i induced NOS, while thrombin has
been shown to have the opposite effect [191, 192].Taken together,
these studies suggest that fibrin deposition during inflammatory
processes affecting the glomeruli depends upon a delicate balance
between locally produced procoagulants and anticoagulants,
which include NO and PG12.
NO in pregnancy
Normal pregnancy is characterized by peripheral and renal
vasodilation, falls in BP and increased GFR, the mechanisms of
which are unknown [193, 194]. A gestational increase in cGMP
production occurs in women and rats [195, 196], and elevations in
26 Rail and Baylis
Modulation of afferent
arteriolar tone
Modulation of
renin release
Modulation
of TGF
p °a
Modulation of Glomerular
mesangial tone" microcirculation
Antithrombogenic
Ultrafiltration
coefficient (Kr)
Mesangial
traffic of
macromolecules
Fig. 3. Schema depicting the physiological
actions of NO at the glomerulus, these actions are
mainly modulated by NO derived from cNOS.
Abbreviations are: TGF, tubuloglomerular
feedback; P0, glomerular capillary pressure;
Qa, glomerular blood flow.
NO production have been reported in pregnant rats [181, 197,
198] which occur in phase with the increased cGMP [1971.
Chronic NO blockade in pregnant rats prevents the renal and
peripheral vasodilation and increase in GFR, and BP is elevated
at term; proteinuria and compromise of maternal and fetal
well-being are also evident [198]. Surprisingly, these pathological
changes occur despite the fact that the late pregnant rat is
relatively resistant to NO blockade with NAME [199]. A dose of
NAME that produced only partial NO blockade in late pregnancy
prevented the gestational rise in NO but left a level of NO
production that is normal for an unblocked virgin, despite which
BP rose [191]. This observation reinforces the concept that
increased NO production is necessary to accomodate the altered
hemodynamic status of pregnancy, particularly since in other
models of chronic hypertension, pregnancy is antihypertensive,
probably because of increased NO production [193, 199]. Re-
cently, pregnancy in guinea pigs and rats has been shown to result
in widespread increases in expression of cNOS [200, 201]. Also,
studies in the conscious, chronically catheterized rat have sug-
gested that the gestational renal vasodilation is NO dependent
[2021. Thus, increased NO production certainly occurs during
pregnancy in the rat and is probably associated with the gesta-
tional vasodilation.
Pregnancy is also a hypercoagulable state with an increased
tendency to develop glomerular thrombosis in women and rats
[193, 203]. Recent studies by Raij have shown that LPS provokes
glomerular thrombosis in late pregnant rats, in a dose that has
no effect in virgins [1811. A lower dose of LPS that has no effect
alone in pregnancy provokes marked glomerular thrombosis when
combined with L-NAME [181]. The glomerular thrombosis is
prevented by L-arginine supplementation. Thus, the normal ges-
tational increase in NO production to accomodate the hemody-
namic changes may lead to a limited maternal reserve capability
for NO synthesis, which may in part underlie the susceptibility for
glomerular thrombosis in pregnancy. The disease of pregnancy,
preeclampsia is characterized by hypertension, proteinuria, low
GFR, glomerular thrombosis and maternal and fetal compromize,
and this is clearly an endothelial cell disease [204]. The observa-
tions in the rat, discussed above, suggest that NO deficiency may
play a primary role in the pathogenesis of preeclampsia. The role
of NO in normal and pre-eclamptic pregnancy in women, has yet
to be determined.
NO and glomerular inflammation
Several studies have shown that glomeruli from rats with
immune-mediated glomerular inflammation have increased pro-
duction of NO [205, 206]. Important questions regarding glomer-
ular NO synthesis during inflammation are: (1) Which cells are
the source of NO? (2) How is NO synthesis regulated? and (3)
Are the effects of NO cytoprotective or cytotoxic? Cattell et al
have provided evidence that in immune glomerular injury, blood
borne glomerular macrophages are a major source of glomerular
NO [206, 207]. However, the concomitant participation of intrin-
sic glomerular cells in the increased NO synthesis/release during
this form of glomerular inflammation cannot be excluded [24,
2071. Moreover, the fact that induction of NOS in macrophages
and in intrinsic glomerular cells is mediated by the interactions of
cytokines such as TNF, IL-i and y interferon, acting in an
autocrine and/or paracrine fashion, makes it difficult to establish
the relative contribution of these cells to NO synthesis [5, 43, 60,
208]. For instance, early during inflammation primed macro-
phages may be the main source of NO. However, the release of
cytokines by these cells within the glomerular environment,
particularly within the mesangium, may induce mesangial cell
synthesis of the same cytokines as well as induce NOS by
autocrine and/or paracrine mechanisms [24—26, 35, 43, 59, 209].
MRL-lpr/lpr mice develop glomerulonephritis during the course
of a spontaneous autoimmune disease which results in inflamma-
tory injury of multiple organs. In these mice synthesis of NO is
increased and inhibitors of NO synthesis attenuate the develop-
ment of giomerulonephritis and arthritis [210]. The sequence of
mechanisms involved in glomerular NO synthesis during inflam-
mation may not only be regulated by agents which induce NOS,
but also by those which inhibit its induction. The latter include
PDGF, TGFI3, IL-4 and IL-b [34—37]. Furthermore, NO synthe-
sis may also be modulated, particularly in glomeruli, by arginase
which metabolizes L-arginine to ornithine. Arginase may lead to
insufficient substrate for NO synthesis [211]. The L-arginine NO
pathway has also been implicated in the functional and histolog-
ical changes which occur in the kidney in response to ureteral
obstruction [212].
The question of whether or not NO synthesis during inflamma-
tion is always injurious is at present unclear (Fig. 3). In this
context, several possibilities should be considered: (1) Generation
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Fig. 4. Schema summarizing the role of NO in glomendar inflammation. The NO is mainly derived from iNOS. The area within the broken box indicates
damaging actions of NO, whereas actions outside of the box are generally regarded as beneficial.
of peroxinitrite (OONO-) by interaction of NO with superoxide
anion (02—) [45, 213] which could either directly or indirectly
(due to its decomposition products NO and OH) initiate lipid
peroxidation and cytotoxicity. GlomerUli undergoing inflamma-
tion have multiple sources of 02—, from macrophages, PMNs,
mesangial cells and endothelial cells [214]. Superoxide dismutase
(SOD) would prevent OONO- generation by acting upon 02—.
On the other hand, SH groups present in proteins may bind NO,
forming S-nitrosothiols (RS-NO) [215]. Formation of RS-NO
under appropriate conditions may have either salutory or patho-
logic consequences. The beneficial effect would come from
"quenching" large amounts of NO, preventing generation of
OONO-. By contrast, nitrosilation of critical free thiols may lead
to inactivation of crucial enzymes resulting in inhibition of
glycolysis, the respiratory chain and the citric acid cycle [43, 45,
215]. (2) NO has been shown to inhibit vascular smooth muscle
and mesangial cell growth and may therefore affect mesangial cell
proliferation [216] in proliferative glomerulonephritis. NO has
been shown to modulate leukocyte adhesion to a variety of cells.
These actions of NO may play an important role in local inflam-
mation. (3) The vasodilatory and antithrombogenic effects of NO
may also be beneficial in glomerular inflammation. Maintenance
of patent glomerular capillary loops is crucial to prevent renal
ischemia since the blood supply to the tubule is post-glomerular
[38, 178].
From the above discussions it becomes clear that delineation of
the time sequence of the generation of NO during glomerular
inflammation as well as determination of the relative quantities of
NO generated may be of importance for designing therapeutic
interventions capable of modulating the L-arginine—NO pathway
and prevent glomerular injury.
Summary
NO, a simple molecule synthesized from L-arginine by NO
synthases, has been identified to play an important role in cell
communication, cell defense and cell injury. The half life of NO is
very short because NO either reacts with superoxide anion (02—),
and/or binds to heme molecules or Fe-S groups present in
proteins. The biological effects of NO depend on both the
concentration of NO at the site of action as well as upon the
specific location where NO is generated. Small quantities of NO
are generated by cNOS such as that present in the vascular
endothelium, while large quantities of nitric oxide are synthesized
by iNOS in response to cytokines or bacterial products. Within the
kidney NO generated by endothelial cNOS participates in the
regulation of the glomerular microcirculation by modifying the
tone of the afferent arteriole and mesangial cells (Fig. 4). In
addition, NO generated by macula densa and the afferent arte-
riole control glomerular hemodynamics via TGF and by modulat-
ing renin release. Therefore NO is important in the physiologic
regulation of glomerular capillary blood pressure, glomerular
plasma flow and the glomerular ultrafiltration coefficient.
Through its actions on glomerular pressures and flows, NO may
also regulate the macro- and micromolecular traffic through the
mesangium. Chronic NO insufficiency causes hypertension and
glomerular damage and may be causally involved in the genesis of
salt dependent hypertension. Increased NO production may be
involved in the early pathogenic hemodynamic changes in diabe-
tes and in the physiologic hemodynamic responses to normal
pregnancy. Maintenance of the antithrombogenic properties of
the endothelium is another important action of NO which inhibits
platelet aggregation and adhesion. Large quantities of NO such as
that synthesized by either glomerular cells or macrophages during
glomerular inflammation may lead to glomerular injury. A better
understanding of the physiology and pathophysiology of NO in
the kidney will lead to the development of new therapeutic
avenues.
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